VKIN yields 247.83% · ABBV yields 3.06%● Live data
📍 VKIN pulled ahead of the other in Year 1
Combined, VKIN + ABBV cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of VKIN + ABBV for your $10,000?
Viking Energy Group, Inc., an exploration and production company, engages in the acquisition and development of oil and natural gas properties in North America. It manufactures and supplies power generation products, services, and custom energy solutions; clean-tech energy systems, including combined heat and power, tier 4 final diesel, and natural gas industrial engines, solar, wind, and storage; designs and assembles electrical control equipment, such as switch gear, synchronization and paralleling gear, distribution, Bi-fuel, and complete power generation production controls; and clean energy and carbon-capture systems to generate clean electricity. The company also engages in developing, patent pending, electric transmission, and distribution of open conductor detection systems to detect a break in a transmission line, distribution line, or coupling failure. The company owns oil and gas leases in Texas, Louisiana, Mississippi, and Kansas. The company was formerly known as Viking Investments Group, Inc. and changed its name to Viking Energy Group, Inc. in March 2017. Viking Energy Group, Inc. was incorporated in 1989 and is headquartered in Houston, Texas.
Full VKIN Calculator →AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Full ABBV Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.